Blackstone sells 13.4 million Legence shares at $54 each

Legence priced a secondary offering of 13,386,185 Class A shares at $54.00 with a 30-day underwriter option for an additional 2,007,927 shares, expected to close on or about April 9, 2026; Legence itself is not selling and proceeds go to Blackstone‑affiliated holders (Blackstone separately plans to sell 11M shares). The company reported Q4 revenue and EBITDA beats of +20% and +40%, backlog grew to $3.7B (+50% YoY, +20% QoQ) with a 1.9x book-to-bill, and the stock is up ~80% over the past year. Multiple banks raised price targets (Stifel $60, RBC $64, BMO/Bernstein $63), suggesting analyst sentiment is constructive despite the secondary offering overhang.

Analysis

The Blackstone-led secondary is a classic near-term liquidity event: the underwriter greenshoe (~15% of the base allotment) creates an asymmetric window where forced supply can overwhelm natural demand, pressuring the tape for ~2–6 weeks around the close and the 30-day stabilization period. Expect borrow availability to increase and borrow costs to fall, lowering the friction for tactical shorts and option sellers; underwriters will likely provide transient support, but that typically ends once the greenshoe is exercised or lapses.

Operationally, LGN’s large backlog and data-center exposure materially de-risk revenue runway versus a generic AEC firm, but the company receives no proceeds from this sale — growth still needs to be funded by cash flow, working capital management, or external financing. That raises a two-way sensitivity: if backlog converts at/above historical margins, the market can absorb the added free float quickly; if conversion slippage or input-cost pressure appears, multiples re-rate faster than peers because investors often discount PE-led exits more aggressively.

Actionable timing/catalysts: the highest-probability volatility cluster is April 9 (expected close) and the 30-day window thereafter, with the next quarterly release as the primary fundamental pivot. Tradeable skew will be highest in the first 10 trading days post-close and again into earnings; use defined-risk option structures or small-sized pair trades to capture the dislocation rather than outright directional exposure pre-close. The consensus buy case looks to underweight the mechanical risk of supply-side selling — smart capital should wait for supply absorption or buy on a disciplined dip rather than chase the pre-offer momentum.

Key Decisions for Investors

• Tactical dip-buy LGN: size 1–2% portfolio position if LGN trades >5% below its April 8 price within 10 trading days post-close (entry = -5% from pre-close), target +20% over 6–12 months, stop -12% to limit execution/earnings risk.
• Defined-risk bullish options (LGN): buy Jun-2026 52.5/62.5 call spread (or nearest strikes) sized to risk 0.5% portfolio — rationale: captures upside if backlog conversion continues while capping premium lost if supply-driven weakness persists; close before greenshoe expiry or after next quarter release; expected payoff ~2–3x if thesis executes.
• Pair trade (lower beta exposure): go long LGN and short FLR (equal $ notionals) for a 6–12 month horizon — thesis: LGN benefits from mission-critical, less cyclical revenue and backlog visibility while FLR is more commodity/cycle exposed. Target LGN relative outperformance of 15–25%; use 10% stop on either leg to control basis risk.
• Sell put to acquire on weakness: sell an out-of-the-money LGN put (one or two strikes below current price) expiring 30–60 days out to collect premium and potentially acquire stock at a cheaper basis if the secondary-driven sell-off materializes. Max loss = assigned shares * (strike - premium); ideal for replacing a full-long should you prefer passive entry.